Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predicting Response to Iron Supplementation in Active Inflammatory Bowel Disease
2022-000894-16Phase 4Terminated
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of ferrous fumarate, ferric maltol, iron dextran, ferric carboxymaltose and ferric derisomaltose in inflammatory bowel disease (IBD), Crohn's disease, autoimmune colitis and 1 more (3 arms), sponsored by Leiden University Medical Center. Primary endpoint: Baseline hepcidin discriminative capacity. Started Mar 2022; status: terminated.
02
Drugs
ferrous fumarateferric maltoliron dextranferric carboxymaltoseferric derisomaltose
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitisiron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2022-000894-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000894-16.